July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Silencing of pro-apoptotic proteins as anti-apoptotic therapy for corneal endothelium
Author Affiliations & Notes
  • Thomas Armin Fuchsluger
    Dept. of Ophthalmology, Heidelberg University Hospital, Germany
    Department of Ophthalmology, Friedrich-Alexander-University, Erlangen, Germany
  • Daniel Thieme
    Department of Ophthalmology, Friedrich-Alexander-University, Erlangen, Germany
  • Friedrich E Kruse
    Department of Ophthalmology, Friedrich-Alexander-University, Erlangen, Germany
  • Siddharth Mahajan
    Department of Ophthalmology, Friedrich-Alexander-University, Erlangen, Germany
  • Footnotes
    Commercial Relationships   Thomas Fuchsluger, None; Daniel Thieme, None; Friedrich Kruse, None; Siddharth Mahajan, None
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 2164. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Thomas Armin Fuchsluger, Daniel Thieme, Friedrich E Kruse, Siddharth Mahajan; Silencing of pro-apoptotic proteins as anti-apoptotic therapy for corneal endothelium. Invest. Ophthalmol. Vis. Sci. 2019;60(9):2164.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Apoptotic cell death has been identified as a major contributor in corneal endothelial cell (EC) loss both during corneal storage and after transplantation. Prevention of apoptosis has been suggested as a strategy to protect EC. To achieve this aim efficient targeting of apoptosis pathway proteins is required. In this proof-of-principle study, siRNA-mediated silencing of pro-apoptotic proteins was used to achieve protection of EC against apoptotic cell death.

Methods : EC were transfected in vitro and ex vivo with anti-Bax and anti-Bak siRNAs at a concentration of 1000nM. EC were studied at different time intervals for the presence of Bax and Bak proteins by western blotting. Metabolic activity was analyzed after transfection by CCK-8 assay. Induction of apoptosis was performed using etoposide (25µg/mL, 21 hours) and staurosporine (250nM, 6 hours) following siRNA transfection. Apoptosis was analyzed with caspase-3 activity assay and by analysis of downstream apoptosis marker proteins (cleaved Lamin A, cleaved PARP) by western blotting. Fluorescence intensity (Ex 360 nm, Em 450 nm) was measured using Fluoroskan Ascent FL fluorometer and luminometer for microplates (Thermo Scientific, Waltham, MA). Both untreated EC and those treated with a control siRNA served as controls.

Results : Silencing of pro-apoptotic proteins Bax and Bak was achieved both in vitro and in vivo. Caspase-3 activity could be significantly reduced after both etoposide (52±3%) and staurosporine (38±6%) by combined Bax+Bak siRNA treatments relative to control-siRNA or untransfected EC. Downstream apoptosis marker proteins (cleaved Lamin A, cleaved PARP) were significantly reduced (83±6%, 79±4%) in Bax+Bak transfected EC compared to controls. In corneal donor tissue, Bax and Bak could be reduced by 30±5%. CCK-8 assay data did not show a significant effect of siRNA treatment on EC viability.

Conclusions : In this study, the proof-of-principle of successful transient reduction in pro-apoptosis proteins Bax and Bak and in downstream apoptosis markers by non-viral siRNA transfer was demonstrated in EC both in vitro and in vivo. The treatment did not result in a significant loss in metabolic activity. Therefore, silencing of pro-apoptotic proteins could be a functional approach to protect EC against apoptosis. These findings could be of high relevance in both corneal cultivation, donor graft cultivation and posterior lamellar graft preparation.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×